Drug Profile
Emactuzumab - Roche
Alternative Names: RG-7155; RO-5509554Latest Information Update: 05 Nov 2023
Price :
$50
*
At a glance
- Originator Roche
- Developer Roche; SynOx Therapeutics; University of Texas M. D. Anderson Cancer Center
- Class Antineoplastics; Immunotherapies; Monoclonal antibodies
- Mechanism of Action Macrophage colony stimulating factor receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase III Giant cell tumour of tendon sheath
- Phase II Fallopian tube cancer; Ovarian cancer; Peritoneal cancer; Solid tumours
- Discontinued Pigmented villonodular synovitis
Most Recent Events
- 28 Aug 2023 No recent reports of development identified for phase-I development in Solid-tumours(Combination therapy, Late-stage disease, Metastatic disease) in Belgium (IV, Infusion)
- 28 Aug 2023 No recent reports of development identified for phase-I development in Solid-tumours(Combination therapy, Late-stage disease, Metastatic disease) in Spain (IV, Infusion)
- 05 Jan 2023 Argonaut Therapeutics has merged with Celleron Therapeutics to form IngenOx Therapeutics